Beranda1JAZZ • BIT
add
Jazz Pharmaceuticals PLC
Tutup sebelumnya
€95,84
Rentang tahun
€87,10 - €105,95
Kapitalisasi pasar
6,87Â M USD
Volume Rata-Rata
1,00
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,05Â M | 2,14% |
Biaya operasional | 710,47Â jt | -0,56% |
Laba bersih | -718,47Â jt | -526,22% |
Margin laba bersih | -68,71 | -517,44% |
Penghasilan per saham | -8,25 | -255,66% |
EBITDA | 392,98Â jt | 8,41% |
Tarif pajak efektif | 2,33% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 1,67Â M | -15,70% |
Total aset | 10,94Â M | -3,68% |
Total liabilitas | 7,24Â M | -4,76% |
Total ekuitas | 3,71 M | — |
Saham yang beredar | 60,66 jt | — |
Harga terhadap nilai buku | 1,57 | — |
Tingkat pengembalian aset | 4,87% | — |
Tingkat pengembalian modal | 5,84% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -718,47Â jt | -526,22% |
Kas dari operasi | 88,86Â jt | -73,18% |
Kas dari investasi | -641,02Â jt | -149,34% |
Kas dari pembiayaan | -124,52Â jt | 22,70% |
Perubahan kas bersih | -672,07Â jt | -667,35% |
Arus kas bebas | 46,83Â jt | -84,01% |
Tentang
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Didirikan
2003
Situs
Karyawan
2.800
